Dexak(Keral)
Dexketoprofen
Dexak and Keral are different trade names for the same medicine.
Dexak is a pain reliever belonging to a group of medicines called nonsteroidal anti-inflammatory drugs (NSAIDs).
It is used for the symptomatic treatment of mild to moderate pain, e.g. muscle pain, painful menstruation, toothache.
If after 3-4 days there is no improvement or if the patient feels worse, they should consult a doctor.
Before starting to take Dexak, the patient should discuss it with their doctor or pharmacist:
Dexketoprofen may mask the symptoms of an infection, such as fever and pain. Therefore, Dexak may delay the use of appropriate infection treatment, which may lead to an increased risk of complications. This has been observed in bacterial pneumonia and bacterial skin infections related to chickenpox. If the patient is taking this medicine during an infection and the symptoms of the infection persist or worsen, they should consult their doctor immediately.
It is recommended to avoid taking this medicine during chickenpox.
This medicine has not been studied in children and adolescents. The safety and efficacy of this medicine have not been established, and therefore, it should not be used in children and adolescents.
The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
Certain medicines should not be taken at the same time as Dexak, and in the case of other medicines, the dose may need to be changed due to concurrent use of Dexak.
The patient should always inform their doctor, dentist, or pharmacist if they are taking any of the following medicines with Dexak:
In case of any doubts related to taking Dexak, the patient should consult their doctor or pharmacist.
Dexak tablets should be swallowed with a sufficient amount of water. Taking the tablets with food can reduce the risk of gastrointestinal side effects.
However, in the case of acute pain, it is recommended to take the medicine on an empty stomach (at least 30 minutes before a meal), which will cause the medicine to be absorbed faster (see section 2 "Taking the medicine with food and drink").
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine.
This medicine should not be taken if the patient is in the last 3 months of pregnancy or during breastfeeding. It may cause kidney and heart problems in the unborn baby. It may also increase the risk of bleeding in the mother and child and cause delayed or prolonged labor.
During the first 6 months of pregnancy, this medicine should not be used unless the doctor considers it absolutely necessary. If treatment is necessary during this period or when trying to conceive, the lowest possible dose should be used for the shortest possible time.
From the 20th week of pregnancy, Dexak, if taken for more than a few days, may cause:
kidney problems in the unborn baby - this may lead to a decrease in the amount of amniotic fluid surrounding the baby (oligohydramnios) or narrowing of the blood vessels (ductus arteriosus) in the baby's heart. If treatment is necessary for a longer period, the doctor may recommend additional monitoring.
This medicine is not recommended for women planning to become pregnant or undergoing fertility treatment. Information on potential fertility effects can be found in section 2 "Warnings and precautions".
Dexak may cause dizziness and fatigue, and therefore may have a minor or moderate effect on the ability to drive vehicles and operate machinery. If such symptoms are observed, the patient should not drive vehicles or operate moving machinery until the symptoms have resolved. In case of doubts, the patient should consult their doctor.
This medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is considered "sodium-free".
This medicine should always be taken exactly as described in the patient leaflet or as directed by a doctor or pharmacist. In case of doubts, the patient should consult their doctor or pharmacist.
The patient should use the smallest effective dose for the shortest necessary period to alleviate the symptoms. If the symptoms of an infection (such as fever and pain) persist or worsen, the patient should consult their doctor immediately (see section 2).
The tablets can be divided into equal doses by breaking them at the score line.
The recommended daily dose is usually half a tablet (12.5 mg) every 4 to 6 hours or 1 tablet (25 mg) every 8 hours, but no more than 3 tablets per day (75 mg).
If after 3-4 days there is no improvement or the patient feels worse, they should contact their doctor. The doctor will inform the patient how many tablets to take per day and for how long.
The dose of Dexak will depend on the type, severity, and duration of the pain in the patient.
In elderly patients or patients with kidney or liver disease, it is recommended to start treatment with a lower total daily dose equivalent to no more than 2 coated tablets (50 mg).
In the case of good tolerance in elderly patients, this initial dose can be increased to the recommended dose for the general population (75 mg).
In the case of acute pain, when faster relief is needed, it is recommended to take the medicine on an empty stomach (at least 30 minutes before a meal), which will cause the medicine to be absorbed faster (see section 2 "Taking the medicine with food and drink").
This medicine should not be used in children and adolescents under the age of 18.
In case of suspected overdose, the patient should inform their doctor or pharmacist or go to the emergency department of the nearest hospital. The patient should remember to take the medicine packaging or patient leaflet with them.
The patient should not take a double dose to make up for a missed dose. The next dose should be taken according to the dosing schedule (see section 3 "How to take Dexak").
In case of any further doubts related to taking this medicine, the patient should consult their doctor or pharmacist.
Like all medicines, Dexak can cause side effects, although not everybody gets them.
Possible side effects are listed below and are grouped according to their frequency of occurrence.
Nausea and/or vomiting, stomach pain, mainly in the upper quadrants, diarrhea, indigestion (dyspepsia).
Dizziness (of labyrinthine origin), drowsiness, sleep disturbances, nervousness, headaches, palpitations, facial flushing, gastritis (gastric inflammation), constipation, dry mouth, bloating with gas, rash, fatigue, pain, feeling of fever and chills, malaise.
Stomach ulcers, gastrointestinal bleeding, or perforation (which may manifest as bloody vomiting or black stools), fainting, hypertension, slowed breathing rate, fluid retention and peripheral edema (e.g. swollen ankles), throat swelling, loss of appetite (anorexia), abnormal sensation, itchy rash, acne, increased sweating, back pain, increased urination, menstrual disorders, prostate disorders, abnormal liver function tests (blood tests), liver cell damage (hepatitis), acute kidney failure.
Anaphylactic reactions (acute hypersensitivity reactions that can lead to anaphylactic shock), skin, lip, eye, or genital ulcers (Stevens-Johnson syndrome and Lyell's syndrome), facial swelling or lip and throat swelling (angioedema), shortness of breath caused by bronchospasm, wheezing, rapid heartbeat, low blood pressure, pancreatitis, blurred vision, tinnitus, skin hypersensitivity reactions, sun hypersensitivity, itching, kidney damage, decreased white blood cell count (neutropenia), decreased platelet count (thrombocytopenia).
The patient should inform their doctor if they notice any side effects, especially those related to the stomach or intestines (e.g. stomach pain, heartburn, or bleeding), if they have had similar side effects in the past due to long-term use of anti-inflammatory medicines, especially if they are elderly.
If a skin rash or any mucosal ulceration (e.g. in the mouth) or any signs of allergy occur, the patient should stop taking Dexak immediately.
During the administration of nonsteroidal anti-inflammatory drugs, fluid retention and edema (especially of the ankles and feet) may occur, as well as increased blood pressure and heart failure.
Taking such medicines as Dexak may be associated with a small increased risk of heart attack (myocardial infarction) or cerebrovascular events (stroke).
In patients with systemic lupus erythematosus or mixed connective tissue disease (immune system disorders affecting connective tissue), the administration of anti-inflammatory medicines may rarely cause fever, headache, and neck stiffness.
The most commonly observed side effects were related to the stomach and intestines. Especially in elderly patients, stomach ulcers, perforation, or gastrointestinal bleeding may occur, in some cases with a fatal outcome.
After taking the medicine, the following have been reported: nausea, vomiting, diarrhea, bloating, constipation, indigestion, abdominal pain, black stools, bloody vomiting, mouth ulcers, exacerbation of colitis, and Crohn's disease. Less frequently, gastritis has been observed.
As with other NSAIDs, hematologic reactions (thrombocytopenia, aplastic anemia, and hemolytic anemia, rarely agranulocytosis, and bone marrow hypoplasia) may occur.
If the patient experiences any side effects, including any possible side effects not listed in the leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
This medicine should not be used after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
[Aclar/Aluminum blister or Aluminum/Aluminum blister:]
There are no special storage temperature recommendations for the medicine. Store in the original packaging to protect from light.
[PVC/Aluminum blister:]
Do not store above 30°C. Store the blister in the outer packaging to protect from light.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Dexak tablets are white, round, coated tablets with a score line.
Dexak is available in packages containing 10, 20, or 30 coated tablets.
For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.
Menarini International Operations Luxembourg S.A.
1, Avenue de la Gare
L-1611 Luxembourg
Luxembourg
Laboratorios Menarini S.A.
Alfons XII 587
08918 Badalona (Barcelona)
Spain
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Irish marketing authorization number:PA 865/2/2
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Spain (RMS), Austria, Belgium, Finland, France, Italy, Luxembourg, Portugal: Ketesse
Cyprus, Greece: Nosatel
Czech Republic: Dexoket
Germany: Sympal
Estonia, Latvia, Lithuania: Dolmen
Hungary: Ketodex
Ireland, Malta, United Kingdom (Northern Ireland): Keral
Netherlands: Stadium
Poland: Dexak
Slovakia: Dexadol
Slovenia: Menadex
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.